First-line crizotinib versus chemotherapy in ALK-positive lung cancer

Solomon, B.J.; Mok, T.; Kim, D.W.; Y. L., W.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; Iyer, S.; Reisman, A.; Wilner, K.D.; Tursi, J.; Blackhall, F.; Boyer, M.; Ganju, V.; Hughes, B.; Pavlakis, N.; Solomon, B.; Varma, S.; Berghmans, T.; Canon, J.L.; Demedts, I.; Janssens, A.; Louis, R.; Pieters, T.; Schallier, D.; Surmont, V.; da Silva, C.M.; Ferreira, C.G.M.; Hirsh, V.; Joy, A.; Laberge, F.; Morzycki, W.; Wierzbicki, R.; Han, B.; Liu, X.; Qin, S.; Shi, Y.; Wang, Y.; Wu, G.; Y. L., W.; Zhou, C.; Ahvonen, J.; Barlesi, F.; Cadranel, J.; Dansin, E.; Fayette, J.; Morere, J.F.; Moro Sibilot, D.; Pujol, J.L.; Quoix, E.; Zalcman, G.; Frickhofen, N.; Schneider, C.P.; Wehler, T.; Mok, T.; So, P.; Cuffe, S.; Bearz, A.; Boni, C.; Cappuzzo, F.; Cognetti, F.; De Braud, F.; De Pas, T.; Galetta, D.; Migliorino, M.; Rocco, D.; Scagliotti, G.; Tagliaferri, P.; Tiseo, M.; Aoe, K.; Hida, T.; Kato, T.; Kozuki, T.; Nakagawa, K.; Niho, S.; Nishio, M.; Nokihara, H.; Satouchi, M.; Seto, T.; Takahashi, T.; Ahn, J.S.; Kim, D.W.; Berchem, G.; Rodriguez, O.A.; Biesma, B.; Dingemans, A.M.; Smit, E.; Helland, A.; Barata, F.; Gorbunova, V.; Manikhas, G.; Orlov, S.; Leong, S.; Lim, H.L.; Soo, R.; Tan, E.H.; Nosworthy, A.; Villena, M.C.; Felip, E.; Lopez, P.G.; Casado, D.I.; Banaclocha, N.M.; Aix, S.P.; Aransay, N.R.; Abreu, D.R.; Perez, J.T.; Gautschi, O.; Pless, M.; Zippelius, A.; Chang, G.C.; Tsai, Y.H.; Shparyk, Y.; Blackhall, F.; Steele, N.; Armenio, V.; Dragnev, K.; Dugan, M.; Gadgeel, S.; Gerber, D.; Graziano, S.; Gurubhagavatula, S.; Horn, L.; Jalal, S.; Lauer, R.; Mehra, R.; Mekhail, T.; Mirshahidi, H.; Pakkala, S.; Polikoff, J.; Raftopoulos, H.; Saleh, M.; Salgia, R.; Waqar, S.

doi:10.1056/NEJMoa1408440

The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer / B.J. Solomon, T. Mok, D.W. Kim, Y.L. Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K.D. Wilner, J. Tursi, F. Blackhall, M. Boyer, V. Ganju, B. Hughes, N. Pavlakis, B. Solomon, S. Varma, T. Berghmans, J.L. Canon, I. Demedts, A. Janssens, R. Louis, T. Pieters, D. Schallier, V. Surmont, C.M. da Silva, C.G.M. Ferreira, V. Hirsh, A. Joy, F. Laberge, W. Morzycki, R. Wierzbicki, B. Han, X. Liu, S. Qin, Y. Shi, Y. Wang, G. Wu, Y.L. Wu, C. Zhou, J. Ahvonen, F. Barlesi, J. Cadranel, E. Dansin, J. Fayette, J.F. Morere, D. Moro Sibilot, J.L. Pujol, E. Quoix, G. Zalcman, N. Frickhofen, C.P. Schneider, T. Wehler, T. Mok, P. So, S. Cuffe, A. Bearz, C. Boni, F. Cappuzzo, F. Cognetti, F. De Braud, T. De Pas, D. Galetta, M. Migliorino, D. Rocco, G. Scagliotti, P. Tagliaferri, M. Tiseo, K. Aoe, T. Hida, T. Kato, T. Kozuki, K. Nakagawa, S. Niho, M. Nishio, H. Nokihara, M. Satouchi, T. Seto, T. Takahashi, J.S. Ahn, D.W. Kim, G. Berchem, O.A. Rodriguez, B. Biesma, A.M. Dingemans, E. Smit, A. Helland, F. Barata, V. Gorbunova, G. Manikhas, S. Orlov, S. Leong, H.L. Lim, R. Soo, E.H. Tan, A. Nosworthy, M.C. Villena, E. Felip, P.G. Lopez, D.I. Casado, N.M. Banaclocha, S.P. Aix, N.R. Aransay, D.R. Abreu, J.T. Perez, O. Gautschi, M. Pless, A. Zippelius, G.C. Chang, Y.H. Tsai, Y. Shparyk, F. Blackhall, N. Steele, V. Armenio, K. Dragnev, M. Dugan, S. Gadgeel, D. Gerber, S. Graziano, S. Gurubhagavatula, L. Horn, S. Jalal, R. Lauer, R. Mehra, T. Mekhail, H. Mirshahidi, S. Pakkala, J. Polikoff, H. Raftopoulos, M. Saleh, R. Salgia, S. Waqar. - In: NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 371:23(2014 Dec 04), pp. 2167-2177. [10.1056/NEJMoa1408440]

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

B. J. Solomon;T. Mok;D. W. Kim;Y. L. Wu;K. Nakagawa;T. Mekhail;E. Felip;F. Cappuzzo;J. Paolini;T. Usari;S. Iyer;A. Reisman;K. D. Wilner;J. Tursi;F. Blackhall;M. Boyer;V. Ganju;B. Hughes;N. Pavlakis;B. Solomon;S. Varma;T. Berghmans;J. L. Canon;I. Demedts;A. Janssens;R. Louis;T. Pieters;D. Schallier;V. Surmont;C. M. da Silva;C. G. M. Ferreira;V. Hirsh;A. Joy;F. Laberge;W. Morzycki;R. Wierzbicki;B. Han;X. Liu;S. Qin;Y. Shi;Y. Wang;G. Wu;Y. L. Wu;C. Zhou;J. Ahvonen;F. Barlesi;J. Cadranel;E. Dansin;J. Fayette;J. F. Morere;D. Moro Sibilot;J. L. Pujol;E. Quoix;G. Zalcman;N. Frickhofen;C. P. Schneider;T. Wehler;T. Mok;P. So;S. Cuffe;A. Bearz;C. Boni;F. Cappuzzo;F. Cognetti;F. De Braud;T. De Pas;D. Galetta;M. Migliorino;D. Rocco;G. Scagliotti;P. Tagliaferri;M. Tiseo;K. Aoe;T. Hida;T. Kato;T. Kozuki;K. Nakagawa;S. Niho;M. Nishio;H. Nokihara;M. Satouchi;T. Seto;T. Takahashi;J. S. Ahn;D. W. Kim;G. Berchem;O. A. Rodriguez;B. Biesma;A. M. Dingemans;E. Smit;A. Helland;F. Barata;V. Gorbunova;G. Manikhas;S. Orlov;S. Leong;H. L. Lim;R. Soo;E. H. Tan;A. Nosworthy;M. C. Villena;E. Felip;P. G. Lopez;D. I. Casado;N. M. Banaclocha;S. P. Aix;N. R. Aransay;D. R. Abreu;J. T. Perez;O. Gautschi;M. Pless;A. Zippelius;G. C. Chang;Y. H. Tsai;Y. Shparyk;F. Blackhall;N. Steele;V. Armenio;K. Dragnev;M. Dugan;S. Gadgeel;D. Gerber;S. Graziano;S. Gurubhagavatula;L. Horn;S. Jalal;R. Lauer;R. Mehra;T. Mekhail;H. Mirshahidi;S. Pakkala;J. Polikoff;H. Raftopoulos;M. Saleh;R. Salgia;S. Waqar

2014

Abstract

The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.

Scheda breve

Scheda completa

Scheda completa (DC)

	Parole chiave
	
			Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases
		
	Settori scientifico-disciplinari dell'articolo
	
			Settore MED/06 - Oncologia Medica
		
	Data di pubblicazione
	
			4-dic-2014
		
	Rivista in ANCE
	
			NEW ENGLAND JOURNAL OF MEDICINE
		
	DOI
	
			https://dx.doi.org/10.1056/NEJMoa1408440
		
	Tipologia
	
			Article (author)
		
	Appare nelle tipologie:
	
			01 - Articolo su periodico

File in questo prodotto:

File	Dimensione	Formato
nejmoa1408440.pdf accesso aperto Tipologia: Publisher's version/PDF Dimensione 569.45 kB Formato Adobe PDF Visualizza/Apri	569.45 kB	Adobe PDF	Visualizza/Apri

Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/426878

Citazioni

1333

2725

2441

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca